Formulation Development
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
VYNE Therapeutics Inc. recently announced the completion of enrollment in the Phase 2a study of FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD). FMX114…
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
Cyclerion Therapeutics, Inc. recently announced research from preclinical studies demonstrating treatment with its lead soluble guanylate cyclase (sGC) stimulator, CY6463, was associated with improved cellular…
INmune Bio, Inc. Presents Data on Combination Therapy With INB03 on Overcoming Resistance to HER2-Targeted Therapies in Breast Cancer
INmune Bio, Inc. has been invited to present data on reversing resistance to HER2-targeted immunotherapy at the HER2-Targeted Therapy Summit in Boston. Mucin 4 (MUC4),…
MD Anderson, Invectys and CTMC Announce Strategic Collaboration for CAR T Cell Therapy Development
The University of Texas MD Anderson Cancer Center, Invectys, Inc., and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National…
Aptamer Group Signs Deal With Flip Gene Therapeutics to Support the Development of Inducible Gene Therapies
Aptamer Group plc has recently negotiated a deal with the biotechnology company Flip Gene Therapeutics to support its novel, inducible gene therapy platform with the…
Kintara Therapeutics Granted Fast Track Designation for VAL-083 for Newly Diagnosed Glioblastoma
Kintara Therapeutics, Inc. recently announced the US FDA has granted Fast Track Designation (FTD) to Kintara’s VAL-083 for the treatment of patients with newly diagnosed…
Kindeva Drug Delivery Announces Collaboration With Synopsys
Kindeva Drug Delivery recently announced a collaboration with Synopsys, Inc. involving the implementation of Synopsys Simpleware automated software solutions to assist in creating….
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD With AIM Biologicals Program
Aeterna Zentaris Inc. recently announced its Autoimmunity Modifying (AIM) Biologicals program has achieved preclinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder (NMOSD)…
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, a Type of Brain Cancer That Affects Predominantly Pediatric Patients
Nuvectis Pharma, Inc. recently announced positive data for NXP900 in a preclinical xenograft model of Group 4 Medulloblastoma presented on June 12, 2022, at SIOPE Brain Tumour Group in Hamburg, Germany, by scientists….
Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia
Veralox Therapeutics recently announced favorable results from the company's Phase 1 clinical program for VLX-1005, a novel 12-LOX inhibitor being developed for the treatment and…
MERXIN & Gerresheimer Worked Successfully Together to Realize the Shortest Possible Time to Market for the MERXIN MRX003 Capsule DPI
Gerresheimer has assumed responsibility for the industrialization of a dry powder inhaler for the treatment of respiratory ailments for MERXIN (United Kingdom), a company that…
Vyluma & Laboratoires Théa Enter Licensing Agreement for the Registration & Commercialization of NVK002 in Canada, Mexico & Select South American Countries
Vyluma, Inc. and Laboratoires Théa recently announced they have recently entered into an exclusive licensing agreement for the registration and commercialization of NVK002 in Canada,…
Pike Therapeutics Announces Positive Pharmacokinetic Animal Study Results & Unexpected Benefits for its Proprietary Weekly CBD Continuous Transdermal Delivery Technology
Pike Therapeutics Inc. has recently completed a preliminary pharmacokinetic rabbit study with its CBD formulations that yielded positive early results. This study demonstrated….
Exavir Therapeutics Announces Preclinical Data for Ultra-Long-Acting Dolutegravir Prodrug XVIR-120
Exavir Therapeutics recently announced the publication of preclinical data for XVIR-120, an investigational agent being developed as a long-acting injectable antiviral for HIV….
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
Olema Pharmaceuticals, Inc. recently announced clinical development progress for OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development…
Replicate Bioscience & Curia Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA
Replicate Bioscience and Curia, formerly AMRI, recently announced they will collaborate on a robust development platform for Replicate’s srRNA therapeutics. The strategic collaboration unites….
First Patient Dosed in Second Phase 2 Add-on Ketamine Trial in Treatment-Resistant Depression
HMNC Brain Health, together with Develco Pharma, recently announced the dosing of the first patient in their second Phase 2 trial with oral prolonged-release Ketamine…
Catalent & MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19
Catalent and MigVax recently announced they have signed a development agreement to leverage Catalent’s proprietary Zydis Bio orally disintegrating tablet (ODT) technology for delivering the…
Editas Medicine & Immatics Enter Strategic Research Collaboration & Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies & Gene Editing for the Treatment of Cancer
Editas Medicine, Inc. and Immatics N.V. recently announced the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and….
Apellis & Sobi Announce First Patient Dosed in Phase 3 Study of Pegcetacoplan for IC-MPGN & C3G, Rare Kidney Diseases With High Unmet Medical Need
Apellis Pharmaceuticals, Inc. and Sobi recently announced the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy,…
